Volume 2.22 | Jun 10

Mammary Cell News 2.22 June 10, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Wnt Proteins Are Self-Renewal Factors for Mammary Stem Cells and Promote Their Long-Term Expansion in Culture
Researchers show that adult mammary glands contain a Wnt-responsive cell population that is enriched for stem cells. [Cell Stem Cell]

Watch Procedure Now  
Learn to Enumerate Mammospheres and Tumorspheres
Cultured in MammoCult®
by STEMCELL Technologies


Overcoming Resistance To One Group Of Breast Cancer Drugs
A team of researchers, led by Carlos Arteaga, at Vanderbilt University Medical Center, Nashville, has identified a mechanism by which human breast cancer cells can develop resistance to one group of drugs used to treat breast cancer, suggesting new approaches to treating the disease. [Press release from Medical News Today discussing online prepublication in the Journal of Clinical Investigation]

Single Radiation Dose During Surgery ‘Effective’ Against Breast Cancer
A single dose of radiation during surgery appears to be at least as effective as lengthier post-surgery courses of radiotherapy for certain patients with breast cancer, a new clinical trial has found. [Press release from Cancer Research UK discussing online prepublication in the Lancet]

Psychological Intervention Provides Enduring Health Benefits for Women with Breast Cancer
Stress-reducing psychological intervention helps to increase survival and quality of life among women with recurrent breast cancer over the long-term, according to results. [Press release from the American Association for Cancer Research discussing online prepublication in Clinical Cancer Research]

Molecular Imaging Helps Predict Breast Cancer Survival
Research is expanding molecular imaging’s role in determining the best course of treatment for recurring breast cancer patients, while offering a means of evaluating certain therapies for potentially positive impact on their chance of survival. [Press release from the Society of Nuclear Medicine discussing research presented at the 57th Annual Meeting of the Society of Nuclear Medicine (SNM)]


CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


Hyperactivation of Phosphatidylinositol-3 Kinase Promotes Escape from Hormone Dependence in Estrogen Receptor-Positive Human Breast Cancer
In order to determine mechanisms of escape from hormone dependence in estrogen receptor-positive breast cancer, researchers established four human breast cancer cell lines after long-term estrogen deprivation. [J Clin Invest]

PMCA2 Regulates Apoptosis During Mammary Gland Involution and Predicts Outcome in Breast Cancer
Here, researchers show that PMCA2 is down-regulated early in mammary involution associated with changes in mammary epithelial cell shape. [Proc Natl Acad Sci U S A]

Fibroblast Growth Factor Receptor Signaling Dramatically Accelerates Tumorigenesis and Enhances Oncoprotein Translation in the Mouse Mammary Tumor Virus-Wnt-1 Mouse Model of Breast Cancer
To investigate the mechanisms involved in fibroblast growth factor (FGF)/Wnt cooperation, researchers genetically engineered a model of inducible FGF receptor signaling in the context of the well-established mouse mammary tumor virus-Wnt-1 transgenic mouse. [Cancer Res]

MLK3 is Critical for Breast Cancer Cell Migration and Promotes a Malignant Phenotype in Mammary Epithelial Cells
Here researchers investigated the effect of mixed-lineage kinase-3 (MLK3) and its signaling to MAPKs in the acquisition of malignancy in breast cancer. [Oncogene]

Constitutive and Chemokine-Dependent Internalization and Recycling of CXCR7 in Breast Cancer Cells to Degrade Chemokine Ligands
Building on the recent observation that CXCR7 sequesters CXCL12, researchers investigated mechanisms for CXCR7-dependent uptake of chemokines. [Oncogene]

The Pro-Metastatic Protein Anterior Gradient-2 Predicts Poor Prognosis in Tamoxifen-Treated Breast Cancers
As targeting the estrogen receptor is responsible for major improvements in cure rates and prevention of breast cancers, researchers have evaluated the pro-oncogenic function of anterior gradient-2 in anti-hormone therapeutic responses. [Oncogene]


Targeted Intraoperative Radiotherapy Versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority Phase III Trial
Researchers compared targeted intraoperative radiotherapy with the conventional policy of whole breast external beam radiotherapy. [Lancet]

Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
Researchers sought to determine whether the combination of ixabepilone plus capecitabine improved overall survival compared with capecitabine alone in patients with metastatic breast cancer previously treated with anthracyclines and taxanes. [J Clin Oncol]

Breast Cancer Dormancy Can Be Maintained by Small Numbers of Micrometastases
In this study, researchers applied a probabilistic mathematical model to long-term follow-up studies of postresection patients to investigate the factors involved in mediating breast cancer dormancy. [Cancer Res]

Endogenous Myoglobin in Human Breast Cancer is a Hallmark of Luminal Cancer Phenotype
Researchers aimed to clarify the incidence and the clinicopathological value of non-muscle myoglobin in a large cohort of non-invasive and invasive breast cancer cases. [Br J Cancer]


Geron Presents Clinical Data on Its Telomerase Inhibitor Drug in Breast Cancer at ASCO
Geron Corporation announced the presentation of data from the clinical trial of imetelstat (GRN163L), the company’s telomerase inhibitor drug, in combination with paclitaxel and bevacizumab in patients with breast cancer. [Press release from Geron Corporation discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Data Presented at ASCO Show Chronix Biomedical’s DNA Blood Tests Detect Breast and Prostate Cancer with 92% Sensitivity and 100% Specificity
Chronix Biomedical reported new data further demonstrating that its DNA blood tests have the potential to accurately detect early stage breast and prostate cancers. [Press release from Chronix Biomedical discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

Phase III Study Results Showed Eisai’s Eribulin Mesylate Significantly Improved Overall Survival in Patients With Locally Recurrent or Metastatic Breast Cancer
Results of a Phase III study showed that Eisai’s eribulin mesylate significantly improved median overall survival compared with Treatment of Physician’s Choice in heavily pre-treated metastatic breast cancer patients. [Press release from Eisai Inc. discussing research presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)]

30 Johns Hopkins Researchers Receive Maryland Stem Cell Funding
Thirty Johns Hopkins researchers have been awarded funding from the Maryland Stem Cell Research Commission under the Maryland Stem Cell Research Act of 2006. [Johns Hopkins Medicine Press Release]


STAR METRICS: New Way to Measure the Impact of Federally Funded Research
A new initiative–Science and Technology for America’s Reinvestment: Measuring the Effect of Research on Innovation, Competitiveness and Science, or STAR METRICS–promises to monitor the impact of federal science investments on employment, knowledge generation, and health outcomes. [National Institutes of Health, United States]

FDA Announces Collaboration with Drugs.com
The U.S. Food and Drug Administration announced that it will collaborate with the website Drugs.com to expand access to the FDA’s consumer health information. [Food and Drug Administration, United States]

Administrative Supplements to Increase Public Awareness of Pediatric Cancers and Available Treatments and Research (NOT-CA-10-026) [National Institutes of Health, United States]

2010 Biological License Application Approvals [Food and Drug Administration, United States]

2010 Biological Device Application Approvals [Food and Drug Administration, United States]


12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom


Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives  |  Events  |  Update Profile  |  Contact Us